48 results
Keyword Aimovig Remove keyword
-
List item
Opinion/decision on a Paediatric investigation plan (PIP): Aimovig, erenumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Neurology
PIP number: EMEA-001664-PIP02-15-M04, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Solution for injection
Decision date: 19/06/2020, Last updated: 17/03/2021, Compliance check: XInvented name Aimovig Active substance erenumab … investigation plan for erenumab (Aimovig), (EMEA-001664-PIP02-15-M04 … investigation plan for erenumab (Aimovig), (EMEA-001664-PIP02-15-M04 … -
List item
Human medicine European public assessment report (EPAR): Aimovig (updated)
erenumab, Migraine Disorders
Date of authorisation: 26/07/2018,
, Revision: 9, Authorised, Last updated: 02/03/2023
Aimovig Headache Disorders, Primary Headache … Aimovig … Aimovig, INN-erenumab 30 Churchill … -
List item
Press release: First monoclonal antibody therapy for prevention of migraine
CHMP, Last updated: 01/06/2018Press release 01/06/2018 Aimovig recommended for marketing … marketing authorisation for Aimovig (erenumab), the first human … for prevention of migraine. Aimovig belongs to a new class of … -
List item
National expert: Marie-Christine Annequin, National Agency For The Safety Of Medicine And Health Products (updated)
- Declaration of interests - 79.84 KB | PDF
- Curriculum Vitae - 18.08 KB | PDF
GAZYVARO, ONCASPAR, REKOVELLE, AIMOVIG, PEGVALIASE, BEVECTRA, Lanadelumab … -
List item
News: Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 May 2018
CHMP, Last updated: 01/06/2018Aimovig … -
List item
Press release: New medicine for the prevention of migraine
CHMP, Last updated: 21/09/2018the positive opinion for Aimovig (erenumab) in May 2018. There … the positive opinion for Aimovig (erenumab) in May 2018. There … the positive opinion for Aimovig (erenumab) in May 2018. There … -
List item
Human medicine European public assessment report (EPAR): Vydura (updated)
Rimegepant, Migraine Disorders
Date of authorisation: 25/04/2022,, Revision: 4, Authorised, Last updated: 21/03/2023
-
List item
Product Management Service (PMS) Webinar on Data Migration (updated)
Online, 14:00 - 15:30 Amsterdam time (CEST), 23/02/2023, Last updated: 20/03/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 2-5 May 2022
European Medicines Agency, Amsterdam, the Netherlands, from 02/05/2022 to 05/05/2022, Last updated: 06/02/2023 -
List item
List of medicines under additional monitoring (updated)
Last updated: 22/02/2023https://portal.dimdi.de/amguifree/am/docoutput/additionaldocs.xhtml?accessid=ami s_off_am_ppv&directdisplay=true&mpdidentifier=2613962 September 2020 Aimovig Erenumab New active substance …
-
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 November - 1 December 2022
European Medicines Agency, Amsterdam, the Netherlands, from 28/11/2022 to 01/12/2022, Last updated: 29/11/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 10-13 January 2022
European Medicines Agency, Amsterdam, the Netherlands, from 10/01/2022 to 13/01/2022, Last updated: 07/10/2022– VYEPTI, erenumab – AIMOVIG (CAP), fremanezumab – AJOVY … -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 17/03/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 29 November-2 December 2021
European Medicines Agency, Amsterdam, the Netherlands, from 29/11/2021 to 02/12/2021, Last updated: 04/10/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 10-13 October 2022
European Medicines Agency, Amsterdam, the Netherlands, from 10/10/2022 to 13/10/2022, Last updated: 23/11/2022 -
List item
CHMP: Agendas, minutes and highlights
Last updated: 08/02/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 8-11 February 2021
European Medicines Agency, Amsterdam, the Netherlands, from 08/02/2021 to 11/02/2021, Last updated: 08/02/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 7-10 June 2021
European Medicines Agency, Amsterdam, the Netherlands, from 07/06/2021 to 10/06/2021, Last updated: 07/06/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 3-6 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 03/05/2021 to 06/05/2021, Last updated: 27/02/2018 -
List item
Committee for Medicinal Products for Human Use (CHMP): 8-11 November 2021
Online, from 08/11/2021 to 11/11/2021, Last updated: 20/01/2022 -
List item
Committee for Medicinal Products for Human Use (CHMP): 17-20 May 2021
European Medicines Agency, Amsterdam, the Netherlands, from 17/05/2021 to 20/05/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 19-22 April 2021
European Medicines Agency, Amsterdam, the Netherlands, from 19/04/2021 to 22/04/2021, Last updated: 07/12/2021 -
List item
Committee for Medicinal Products for Human Use (CHMP): 22-25 February 2021
European Medicines Agency, Amsterdam, the Netherlands, from 22/02/2021 to 25/02/2021, Last updated: 07/12/2021 -
List item
Download medicine data
Last updated: 02/12/2021 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 11-14 January 2021
Virtual meeting, from 11/01/2021 to 14/01/2021, Last updated: 27/02/2018